Trial Profile

A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
Indications Carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Acronyms JAVELIN CHEMOTHERAPY MEDLEY
Sponsors Pfizer

17 Mar 2023 Status changed from completed to discontinued.
20 Jan 2023 This trial has been completed in Italy (End Date: 12 Oct 2022) according to European Clinical Trials Database record.
19 Jan 2023 This trial has been completed in Hungary (End Date: 20 Dec 2022) according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com